MDACC Study No:BTTC09-01 ( NCT No: NCT01434602)
Title:A Phase I-II trial everolimus and sorafenib in Patients with Recurrent High-Grade Gliomas
Principal Investigator:Marta Penas-Prado
Treatment Agent:Everolimus; Sorafenib
Study Status:Open
Study Description:The goal of Phase 1 of this clinical research study is to find the highest
tolerable dose and best schedule of the combination of everolimus and sorafenib
that can be given to patients with malignant glioma.

The goal of Phase 2 of this study to learn if the combination of everolimus and
sorafenib can help to control malignant glioma. The safety of this combination
will also be studied in both phases.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I/Phase II
Treatment Agents:Everolimus
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Bayer Pharmaceuticals
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marta Penas-Prado
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults